key: cord-0875125-igjk7c83
authors: Lee, Won Sik; Rhee, Dong-Kwon
title: Corona-Cov-2 (COVID-19) and ginseng: Comparison of possible use in COVID-19 and influenza
date: 2021-02-18
journal: J Ginseng Res
DOI: 10.1016/j.jgr.2020.12.005
sha: 2e1d790f7ca84aee6e1a8c9c0f16c7c421afbbc2
doc_id: 875125
cord_uid: igjk7c83

In the 1918 influenza pandemic, more than 95% of mortalities were ascribed to bacterial pneumonia. After the primary influenza infection, the innate immune system is attenuated, and the susceptibility to bacteria is increased. Subsequent bacterial pneumonia exacerbates morbidity and increases the mortality rate. Similarly, COVID-19 infection attenuates innate immunity and results in pneumonia. In addition, the current pneumococcal conjugate vaccine may have limited defense against secondary pneumococcal infection after influenza infection. Therefore, until a fully protective vaccine is available, a method of increasing immunity may be helpful. Ginseng has been shown to increase the defense against influenza in clinical trials and animal experiments, as well as the defense against pneumococcal pneumonia in animal experiments. Based on these findings, ginseng is suspected to be helpful for providing immunity against COVID-19.

pneumonia. After the primary influenza infection, the innate immune system is attenuated, 23 and the susceptibility to bacteria is increased. Subsequent bacterial pneumonia exacerbates 24 morbidity and increases the mortality rate. Similarly, COVID-19 infection attenuates innate 25 immunity and results in pneumonia. In addition, the current pneumococcal conjugate vaccine 26 may have limited defense against secondary pneumococcal infection after influenza infection. 27 Therefore, until a fully protective vaccine is available, a method of increasing immunity may 28 be helpful. Ginseng has been shown to increase the defense against influenza in clinical trials 29 and animal experiments, as well as the defense against pneumococcal pneumonia in animal 30 experiments. Based on these findings, ginseng is suspected to be helpful for providing 31 immunity against COVID-19. 

The population older than 65 years is increasing globally. Since aged persons are highly 82 susceptible to respiratory diseases due to weakened immune system, the mortality rate of this 83 population could be higher than ever before. The mortality rate in those older than 70 years induced by not only influenza infection, but also IFN [13] . ACE2 is present in a wide variety 98 of cells comprising not only lung, but also brain, heart, placenta, pancreas, and enterocytes, 99 suggesting that COVID-19 can affect many organs [13] . The COVID-19 spike protein is 

Limited efficacy of antibacterial 165 vaccination against secondary serotype 3 pneumococcal pneumonia following influenza 166 infection

Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan -implications for the 169 ability to produce long-lasting protective antibodies against SARS-CoV-2. medRxiv

SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene 174 in human airway epithelial cells and is detected in specific cell subsets across tissues

CoV-2 strategically mimics proteolytic activation of human ENaC. Elife

Proof of the mysterious efficacy of ginseng: basic and clinical 182 trials: clinical effects of medical ginseng, korean red ginseng: specifically, its anti-stress 183 action for prevention of disease

Protective effect of Korean red ginseng extract on the infections by H1N1 and H3N2 187 influenza viruses in mice

Antiviral Activity of Fermented Ginseng Extracts against a Broad Range of 18

Ginseng-containing diet helps to protect mice and ferrets from the lethal infection by highly 195 pathogenic H5N1 influenza virus

Immunomodulatory 198 activity of red ginseng against influenza A virus infection

Panax 201 ginseng aqueous extract prevents pneumococcal sepsis in vivo by potentiating cell survival 202 and diminishing inflammation

Korean red ginseng enhances pneumococcal Δpep27 205 vaccine efficacy by inhibiting reactive oxygen species production